Our Story
We initially were focused on developing our proprietary Spongilla technology for the prescription dermatology market, but in September 2025, we announced a strategic pivot to leverage our knowledge of our Spongilla technology to be used with active OTC pharmaceutical ingredients for the direct-to-consumer market. This new business model will allow us to directly reach the broader consumer market in dermatology, including in acne, psoriasis, and seborrheic dermatitis.
Our diverse and experienced management team has spent years researching and learning about our Spongilla technology and its many unique and useful features. We believe this experience will aid us in the development and distribution of differentiated pharmaceutical products that patients want to use. These products will be safe, effective, and affordable for patients as well as easily accessible. We are well underway developing our initial once-weekly acne kit, that we plan to launch in the middle of 2026, with additional product candidates anticipated to follow.